0.6264

0.02% 0.01

Nektar Therapeutics (NKTR)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$0.6364

Offen:

$0.63

24-Stunden-Volumen:

642.53K

Relative Volume:

0.28

Marktkapitalisierung:

$112.39M

Einnahmen:

$90.12M

Nettoeinkommen (Verlust:

$-276.06M

KGV:

-0.429

EPS:

-1.46

Netto-Cashflow:

$-193.47M

1W Leistung:

+5.40%

1M Leistung:

-26.31%

6M Leistung:

-54.21%

1J Leistung:

-48.67%

1-Tages-Spanne:

$0.6114

$0.65

1-Wochen-Bereich:

$0.5904

$0.6809

52-Wochen-Spanne:

$0.432

$1.928

Nektar Therapeutics Stock (NKTR) Company Profile

Firmenname

Nektar Therapeutics

Sektor

Healthcare (1152)

Branche

Biotechnology (660)

Telefon

(415) 482-5300

Adresse

455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA

Mitarbeiter

Twitter

@nektarnews

Nächster Verdiensttermin

2025-03-12

Neueste SEC-Einreichungen

NKTR's Discussions on Twitter

Vergleichen Sie NKTR mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
NKTR Nektar Therapeutics	0.6319	112.39M	90.12M	-276.06M	-193.47M	-1.46
VRTX Vertex Pharmaceuticals Inc	473.93	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	558.78	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	594.54	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	229.93	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	228.75	26.16B	3.81B	-644.79M	-669.77M	-6.24

Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-04-11	Hochstufung	Jefferies	Hold → Buy
2025-03-14	Hochstufung	Oppenheimer	Perform → Outperform
2025-01-08	Eingeleitet	B. Riley Securities	Buy
2024-12-10	Eingeleitet	H.C. Wainwright	Buy
2024-11-04	Eingeleitet	Piper Sandler	Overweight
2024-09-30	Fortgesetzt	BTIG Research	Buy
2024-06-28	Eingeleitet	Rodman & Renshaw	Buy
2023-11-20	Fortgesetzt	JP Morgan	Underweight
2023-11-09	Hochstufung	TD Cowen	Market Perform → Outperform
2023-05-10	Hochstufung	Jefferies	Underperform → Hold
2023-02-24	Herabstufung	Jefferies	Hold → Underperform
2022-08-08	Herabstufung	JP Morgan	Neutral → Underweight
2022-05-31	Fortgesetzt	Jefferies	Hold
2022-04-18	Herabstufung	Goldman	Neutral → Sell
2022-03-15	Herabstufung	Cowen	Outperform → Market Perform
2022-03-15	Herabstufung	Mizuho	Buy → Neutral
2022-03-14	Herabstufung	BTIG Research	Buy → Neutral
2022-03-14	Herabstufung	BofA Securities	Neutral → Underperform
2022-03-14	Herabstufung	Stifel	Buy → Hold
2022-03-14	Herabstufung	William Blair	Outperform → Mkt Perform
2022-03-09	Hochstufung	Oppenheimer	Perform → Outperform
2021-11-08	Hochstufung	The Benchmark Company	Hold → Buy
2021-09-10	Eingeleitet	BofA Securities	Neutral
2021-06-28	Hochstufung	Stifel	Hold → Buy
2021-05-18	Fortgesetzt	Goldman	Neutral
2021-02-22	Herabstufung	The Benchmark Company	Buy → Hold
2021-01-06	Eingeleitet	Stifel	Hold
2020-09-14	Eingeleitet	JP Morgan	Neutral
2020-06-10	Herabstufung	CFRA	Hold → Sell
2020-05-12	Bestätigt	H.C. Wainwright	Neutral
2020-04-22	Eingeleitet	The Benchmark Company	Buy
2020-03-30	Hochstufung	Goldman	Sell → Neutral
2020-03-04	Eingeleitet	Barclays	Overweight
2020-02-03	Hochstufung	Mizuho	Neutral → Buy
2019-10-24	Eingeleitet	Oppenheimer	Perform
2019-10-08	Herabstufung	Goldman	Buy → Sell
2019-08-09	Herabstufung	JP Morgan	Overweight → Neutral
2019-08-09	Herabstufung	Jefferies	Buy → Hold
2019-08-09	Herabstufung	Mizuho	Buy → Neutral
2019-03-15	Eingeleitet	SVB Leerink	Mkt Perform
2018-12-13	Eingeleitet	Goldman	Buy
2018-06-11	Herabstufung	H.C. Wainwright	Buy → Neutral
2018-06-04	Bestätigt	H.C. Wainwright	Buy
2018-04-20	Eingeleitet	Seaport Global Securities	Buy
2018-04-13	Fortgesetzt	Piper Jaffray	Overweight
2018-04-06	Bestätigt	Mizuho	Buy
2018-04-02	Fortgesetzt	H.C. Wainwright	Buy

Alle ansehen

Nektar Therapeutics Aktie (NKTR) Neueste Nachrichten

Apr 16, 2025

Treg Cell-Based Therapies Pipeline: 51+ Innovators Shaping the Future of Immunotherapy | DelveInsight - openPR.com

Apr 16, 2025

Jefferies Upgrades Nektar Therapeutics to Buy, Doubles Price Target to $2.00 - Yahoo Finance

Apr 11, 2025

Nektar Therapeutics Shares Rise After Upgrade From Jefferies - marketscreener.com

Apr 11, 2025

Why Is Nektar (NKTR) Down 38.8% Since Last Earnings Report? - Yahoo Finance

Apr 11, 2025

Nektar Therapeutics stock upgraded at Jefferies (NKTR:NASDAQ) - Seeking Alpha

Apr 11, 2025

Assessing Nektar Therapeutics: Insights From 5 Financial Analysts - Benzinga

Apr 11, 2025

Jefferies Upgrades Nektar Therapeutics to Buy From Hold, Adjusts Price Target to $2 From $1 - MarketScreener

Apr 11, 2025

Jefferies raises Nektar stock to buy, doubles price target By Investing.com - Investing.com India

Apr 11, 2025

Jefferies Upgrades Nektar Therapeutics (NKTR) to Buy - StreetInsider

Apr 11, 2025

Apr 10, 2025

IL-2 ADding contenders in eczema strategy - BioWorld MedTech

Apr 10, 2025

Apr 09, 2025

Nektar Therapeutics stock hits 52-week low at $0.44 By Investing.com - Investing.com Canada

Apr 09, 2025

Nektar Therapeutics stock hits 52-week low at $0.44 - Investing.com

Apr 09, 2025

Apr 04, 2025

Little Excitement Around Nektar Therapeutics' (NASDAQ:NKTR) Revenues As Shares Take 29% Pounding - simplywall.st

Apr 04, 2025

Mar 31, 2025

Q1 Dermatology Drug & Device Report: FDA Approvals & Pipeline Updates - Dermatology Times

Mar 31, 2025

Mar 29, 2025

Nektar Therapeutics announces $75 million equity distribution - Investing.com Australia

Mar 29, 2025

Mar 28, 2025

Nektar Therapeutics announces $75 million equity distribution By Investing.com - Investing.com South Africa

Mar 28, 2025

Nektar TherapeuticsEnters Equity Distribution Agreement Up To $75 MillionSEC Filing - Marketscreener.com

Mar 28, 2025